BNP Paribas Financial Markets Takes Position in Certara, Inc. (NASDAQ:CERT)

BNP Paribas Financial Markets bought a new stake in Certara, Inc. (NASDAQ:CERT) in the fourth quarter, HoldingsChannel reports. The fund bought 279,061 shares of the company’s stock, valued at approximately $2,972,000.

A number of other large investors have also modified their holdings of the stock. Ameriprise Financial Inc. grew its stake in shares of Certara by 864.0% in the fourth quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company’s stock valued at $40,253,000 after buying an additional 3,387,590 shares in the last quarter. Algert Global LLC acquired a new stake in shares of Certara in the fourth quarter valued at about $662,000. ArrowMark Colorado Holdings LLC grew its stake in shares of Certara by 164.2% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock valued at $66,171,000 after buying an additional 3,861,674 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Certara by 60.5% in the fourth quarter. Jane Street Group LLC now owns 236,591 shares of the company’s stock valued at $2,520,000 after buying an additional 89,198 shares in the last quarter. Finally, Northern Trust Corp grew its stake in shares of Certara by 14.0% in the fourth quarter. Northern Trust Corp now owns 877,010 shares of the company’s stock valued at $9,340,000 after buying an additional 108,038 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Trading Down 0.9%

NASDAQ:CERT opened at $11.62 on Friday. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The business’s 50 day moving average is $11.70 and its two-hundred day moving average is $11.71. Certara, Inc. has a 52 week low of $8.64 and a 52 week high of $17.76. The company has a market cap of $1.89 billion, a PE ratio of -58.10, a P/E/G ratio of 9.29 and a beta of 1.57.

Certara (NASDAQ:CERT) last released its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.04. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. During the same quarter last year, the business posted $0.10 EPS. Certara’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. KeyCorp increased their target price on Certara from $15.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, April 16th. William Blair restated a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Barclays upgraded Certara from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. TD Cowen started coverage on Certara in a research note on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective for the company. Finally, Robert W. Baird raised their price objective on Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Certara currently has an average rating of “Moderate Buy” and a consensus target price of $15.67.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.